Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-03-16
1993-06-22
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31445
Patent
active
052216799
ABSTRACT:
The invention relates to a method of treating therapy-resistant schizophrenia which includes administering a therapeutically effective amount of melperone (4-fluro-.gamma.-(4-methyl-piperidino)-butyrophenone) or an acceptable acid salt thereof.
REFERENCES:
patent: 3978216 (1976-08-01), Fuxe
patent: 4084000 (1978-04-01), Fuxe
patent: 4284638 (1981-08-01), Waldmeier
patent: 4808630 (1989-02-01), Straw
C.A. 112: (5) 30494n (1990).
The Merck Index--Eleventh Edition (1989)--#2421.
N. C. Andreason and S. O. Olsen, "Negative v. Positive Schizophrenia", Archives General Psychiatry, 1982, 39:789-794.
J. Endicott and R. L. Spitzer, "A Diagnostic Interview", Archives of General Psychiatry, 1978, 35:837-844.
S. Gershon, "Update on Drug Development", Psychopharmacology Bulletin, 1980 16(3):32-35.
R. Grohmann et al., "Adverse Effects of Clozapine" Physcopharmacology, 1989, Supplement to vol. 9:S101-S104.
H. P. Hippus, "The History of Clozapine", Psychopharmacology, Supplement to vol. 99: S3-S5 1989.
J. M. Kane, "Treatment of Schizophrenia", Special Report: Schizophrenia, 1987, N.I.M.H., Treatment of Schizophrenia, in: Schizophrenia Bulletin, 13:133-156, 1987.
J. M. Kane and J. Lieberman, "Maintenance Pharmacotherapy and Schizophrenia", Pharmacotherapy: The Third Generation of Progress, 1987, ed. H. Y. Meltzer, Raven Press, New York, pp. 1103-1109.
J. E. Overall and D. R. Gorham, "The Brief Psychiatric Rating Scale", Psychological Reports, 1962, 10:799-812.
Diagnostic and Statistical Manual of Mental Disorders (3rd Ed.), American Psychiatric Assoc., Washington, D.C., 1987, pp. 187-198.
C. A. Altar et al., "Dopamine Neurochemical Profile of Atypical Antipsychotics Resembles that of D-1 Antagonists", Archives of Pharmacology, 1988, 388:162-168.
I. Christensen, et al., "Additional Studies on Side Effects of Melperone in Long-term Therapy for 1-20 Years in Psychiatric Patients", Arzneim.-Forch./Drug Research, 1986, 36:855-860.
G. A. Gudelsky, et al., "Neuroendocrine Effects of Typical and Atypical Antipsycotics in the Rat", Psychopharmacology Bulletin, 1987, 23:483-486.
G. A. Gudelsky, and A. Y. Meltzer, "Activation of Tuberoinfundibular Dopamine Neurons Following the Acute Administration of Atypical Antipsycotics", Neuropsychopharmacology 1989, 2:45-51.
J. M. Kane et al., "Clozapine in Treatment-Resistant Schizophrenics", Psychopharmacology Bulletin, 1988, 24:62-67.
H. Y. Meltzer et al., "Clozapine-Like Drugs", Psychopharmacology Bulletin, 1980, 16(3):32-35.
H. Y. Meltzer et al., "Melperone and Clozapine: Neuroendocrine Effects of Atypical Neuroleptic Drugs", Acta Psychiatr. Scand., 1989, Suppl. 352-24-29.
J. F. Nash et al., "Antagonism of Serotonin Receptor Mediated Neuroendocrine and Temperature Response by Atypical Neuroleptics in the Rat", European Journal of Pharmacology, 1988, 151:462-469.
Case Western Reserve University
Criares T. J.
Waddell Frederick E.
LandOfFree
Method of treating therapy resistant schizophrenia with melperon does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating therapy resistant schizophrenia with melperon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating therapy resistant schizophrenia with melperon will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1441185